Raymond James Financial
TENX icon

Raymond James Financial’s Tenax Therapeutics TENX Stock Holding History

Raymond James Financial’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,503
Closed -$8.66K – 6599
2025
Q2 		$8.66K Buy
+1,503
New +$8.69K ﹤0.01% 5977

Other funds holding TENX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Raymond James Financial's TENX Position: Q3 2025 in Review

Raymond James Financial sold out of Tenax Therapeutics (TENX) in Q3 2025, closing a stake of 1,503 shares — an estimated $8.66K sold.

Raymond James Financial first reported a position in TENX in Q2 2025 and held it in 1 quarter. The position peaked at $8.66K in Q2 2025. 34 funds tracked by Wall St. Rank hold TENX as of Q3 2025.

  • Raymond James Financial reported no remaining Tenax Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,503 Tenax Therapeutics shares in Q3 2025, an estimated $8.66K.
  • Raymond James Financial first reported a position in Tenax Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Tenax Therapeutics position peaked at $8.66K in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.